Newcourt Acquisition Corp
Status: Closed Deal
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $250.00M |
---|---|
IPO Date | Oct 20, 2021 |
CEO | Marc Balkin |
Left Lead | Cantor Fitzgerald |
IPO Cash in Trust | 102.0% |
SPAC Tenor | 15 + 6 + 6 + 1 |
IPO Sector | Financial â–¶ |
IPO Geography | EEMEA |
Target Company | Psyence Biomed Corp |
Deal Announced | Jan 9, 2023 |
Deal Size, $M | $111.00M |
Deal Sector | Healthcare |
Deal Geography | Global |
SEC Filings |
www.sec.gov |
Approval Vote | Jan 18, 2024 |
Amendment Vote | Jan 22, 2024 |
Closing Date | Jan 25, 2024 |
Formerly NCAC
PBM
PBMWW
Price | $1.23 $0.02 |
---|---|
Last closing price | $1.24 |
H/L, today | $1.15 / $1.27 |
Volume, today | 198,948 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Newcourt Acquisition Corp:
- Structure and cap table
- 6 directors & officers
- 49 filings and events
- 1 underwriters
- 2 deal advisors
- 3 legal advisors
Key Dates
Sign in to view structure, cap table, and calendar of events.
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Title | Name | Age |
---|---|---|
Chairman of the Board of Directors | Michael Jordaan | 52 |
CEO | Marc Balkin | 47 |
CFO | Jurgen van de Vyver | 34 |
Director | Simran Aggarwal | 48 |
Director | Rohit Bodas | 45 |
Director | Nicole Farb | 42 |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters | |||
---|---|---|---|
Book Runner | Cantor Fitzgerald | 22,000,000 | units |
22,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
5.00 | % |
Sign in to view more advisor data.